Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

• Published in: Clinical & translational oncology 2025-01
• Main Authors: Bolek, Hatice, Kuzu, Omer Faruk, Sertesen Camoz, Elif, Sim, Saadet, Sekmek, Serhat, Karakas, Hilal, Isık, Selver, Günaltılı, Murat, Akkus, Aysun Fatma, Tural, Deniz, Arslan, Cagatay, Goksu, Sema Sezin, Sever, Ozlem Nuray, Karadurmus, Nuri, Karacin, Cengiz, Sendur, Mehmet Ali Nahit, Yekedüz, Emre, Urun, Yuksel
• Format: Article
• Language: English
• ISSN: 1699-3055; 1699-3055
• DOI: 10.1007/s12094-024-03813-w

Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy. A retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (×10 /L). We categorized patients into two categories based on their median GLR level. The analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7-17.4) compared to 7.79 months (95% CI 6.6-9.0) in the GLR-high group (p